منابع مشابه
Epigenetics and Targeted Therapy in Acute Leukemia
Chromatin is a highly ordered structure consisting of repeats of nucleosomes connected by linker DNA. It consists of DNA, histone, and nonhistone proteins condensed into nucleoprotein complexes and it functions as the physiological template of all eukaryotic genetic information. Histones are small basic proteins containing a globular domain and a flexible charged NH2 terminus known as the histo...
متن کاملTargeted Nanoparticles for Pediatric Leukemia Therapy
The two major forms of leukemia, acute lymphoblastic leukemia (ALL) and acute myeloid leukemia (AML), account for about one-third of the malignancies diagnosed in children. Despite the marked successes in ALL and AML treatment, concerns remain regarding the occurrence of resistant disease in subsets of patients, the residual effects of therapy that often persist for decades beyond the cessation...
متن کاملBRAF inhibitor: targeted therapy in hairy cell leukemia.
In this issue of Blood, Dietrich et al report that the low-dose BRAF inhibitor, vemurafenib, is highly effective in refractory hairy cell leukemia. Despite enormous progress that has been made with purine nucleoside analogs as the initial treatment of patients with hairy cell leukemia, the relapse rate and eventual development of refractory disease mandate the continued search for effective new...
متن کاملCD126 and Targeted Therapy with Tocilizumab in Chronic Lymphocytic Leukemia.
PURPOSE IL6 promotes tumor growth and signal transduction via both its membrane-bound (CD126) and soluble receptors (sCD126). We aimed to study whether the levels of CD126 expression in chronic lymphocytic leukemic (CLL) cells can predict in vitro and in vivo treatment response. EXPERIMENTAL DESIGN The levels of membrane-bound CD126 expression were determined on freshly isolated CLL B cells (...
متن کاملResistance to HER2-targeted therapy
Production and approval of trastuzumab (Herceptin®) for the treatment of metastatic breast cancer (MBC) was a millstone in antibody-based targeted therapy in the cancer treatment. However, despite the early success in the clinical trials, trastuzumab failed to appreciate the initial attraction due to development of resistance to the drug. The majority of patients who benefit from the drug...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: Modern Pathology
سال: 2008
ISSN: 0893-3952,1530-0285
DOI: 10.1038/modpathol.2008.13